Cutler Group’s Core Laboratories CLB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q3
– Sell
-400
Closed -$1K – 5760
2021
Q2
$1K Buy
+400
New +$14.3K ﹤0.01% 5230
2017
Q4
– Sell
-6,300
Closed -$6K – 4980
2017
Q3
$6K Sell
6,300
-4,000
-39% -$388K ﹤0.01% 4192
2017
Q2
$13K Sell
10,300
-11,900
-54% -$1.28M ﹤0.01% 3870
2017
Q1
$125K Buy
22,200
+5,500
+33% +$639K 0.01% 1543
2016
Q4
$40K Buy
+16,700
New +$1.85M ﹤0.01% 2766
2016
Q3
– Sell
-10,700
Closed -$61K – 6703
2016
Q2
$61K Sell
10,700
-24,500
-70% -$2.96M ﹤0.01% 2159
2016
Q1
$63K Buy
35,200
+11,800
+50% +$1.23M ﹤0.01% 2076
2015
Q4
$23K Buy
+23,400
New +$2.68M ﹤0.01% 3259

Other funds holding CLB

Cutler Group's CLB Position: Q2 2021 in Review

Cutler Group sold out of Core Laboratories (CLB) in Q2 2021, closing a stake of 230 shares — an estimated $8.24K sold.

Cutler Group first reported a position in CLB in Q4 2015 and held it in 11 quarters. The position peaked at $990K in Q3 2016. 195 funds tracked by Wall St. Rank hold CLB as of Q2 2021.

  • Cutler Group reported no remaining Core Laboratories position as of Q2 2021 after selling out during the quarter.
  • Cutler Group sold 230 Core Laboratories shares in Q2 2021, an estimated $8.24K.
  • Cutler Group first reported a position in Core Laboratories in Q4 2015 and held it in 11 quarters.
  • Cutler Group's Core Laboratories position peaked at $990K in Q3 2016.
  • 195 funds tracked by Wall St. Rank held Core Laboratories as of Q2 2021.

Based on Cutler Group's 13F filing for Q2 2021, filed 19 Jul 2021.